BACKGROUND:Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis. Treatment with a pulmonary vasodilator has never been studied systematically. We evaluated the effect of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right ventricular dilatation. METHODS: In a randomized, single-blind study, 14 patients with acute pulmonary embolism received epoprostenol or placebo infusion for 24 hours on top of conventional treatment. Effects on right ventricular end-diastolic diameter, systolic pulmonary artery pressure, right ventricle fractional area change and tricuspid annular plane systolic excursion were assessed by serial echocardiography. Furthermore Troponin T and NT-proBNP were measured serially. RESULTS: Compared to placebo, epoprostenol was associated with a relative change from baseline in right ventricular end-diastolic diameter of +2% after 2.5 hours and -8% after 24 hours. Epoprostenol did not have a significant effect on systolic pulmonary artery pressure, right ventricular fractional area change and tricuspid annular plane systolic excursion, nor on biochemical parameters. CONCLUSION: In patients with acute pulmonary embolism and right ventricular overload, treatment withepoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload. REGISTRATION: URL: NCT01014156Medical ethical committee: Medisch-ethische toetsingscommissie (METc) from the VUmc (free university medical centre).
RCT Entities:
BACKGROUND:Right ventricular dilatation in the setting of acute pulmonary embolism is associated with an adverse prognosis. Treatment with a pulmonary vasodilator has never been studied systematically. We evaluated the effect of epoprostenol on right ventricular diameter and function in patients with acute pulmonary embolism and right ventricular dilatation. METHODS: In a randomized, single-blind study, 14 patients with acute pulmonary embolism received epoprostenol or placebo infusion for 24 hours on top of conventional treatment. Effects on right ventricular end-diastolic diameter, systolic pulmonary artery pressure, right ventricle fractional area change and tricuspid annular plane systolic excursion were assessed by serial echocardiography. Furthermore Troponin T and NT-proBNP were measured serially. RESULTS: Compared to placebo, epoprostenol was associated with a relative change from baseline in right ventricular end-diastolic diameter of +2% after 2.5 hours and -8% after 24 hours. Epoprostenol did not have a significant effect on systolic pulmonary artery pressure, right ventricular fractional area change and tricuspid annular plane systolic excursion, nor on biochemical parameters. CONCLUSION: In patients with acute pulmonary embolism and right ventricular overload, treatment with epoprostenol did not improve right ventricular dilatation or any other measured variables of right ventricular overload. REGISTRATION: URL: NCT01014156Medical ethical committee: Medisch-ethische toetsingscommissie (METc) from the VUmc (free university medical centre).
Authors: Stavros Konstantinides; Annette Geibel; Gerhard Heusel; Fritz Heinrich; Wolfgang Kasper Journal: N Engl J Med Date: 2002-10-10 Impact factor: 91.245
Authors: S Grifoni; I Olivotto; P Cecchini; F Pieralli; A Camaiti; G Santoro; A Conti; G Agnelli; G Berni Journal: Circulation Date: 2000-06-20 Impact factor: 29.690
Authors: Harry R Büller; Giancarlo Agnelli; Russel D Hull; Thomas M Hyers; Martin H Prins; Gary E Raskob Journal: Chest Date: 2004-09 Impact factor: 9.410
Authors: Roald J Roeleveld; Anton Vonk-Noordegraaf; J Tim Marcus; Jean G F Bronzwaer; Koen M J Marques; Pieter E Postmus; Anco Boonstra Journal: Chest Date: 2004-02 Impact factor: 9.410
Authors: Carlos A Dias; Evandro M Neto-Neves; Marcelo F Montenegro; Jose E Tanus-Santos Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2011-10-02 Impact factor: 3.000
Authors: Jeffrey A Kline; Cassandra L Hall; Alan E Jones; Michael A Puskarich; Ronald A Mastouri; Tim Lahm Journal: Am Heart J Date: 2017-01-27 Impact factor: 4.749
Authors: Robin Condliffe; Charlie A Elliot; Rodney J Hughes; Judith Hurdman; Rhona M Maclean; Ian Sabroe; Joost J van Veen; David G Kiely Journal: Thorax Date: 2013-12-16 Impact factor: 9.139